7
Nov
2022
Tag: cancer
19
Sep
2022
Bionest
ASCO 2022 – Part 1: Redefining Breast Cancer Classification and Treatment
An important new development in breast cancer greatly expands the number of patients who might benefit from HER2-targeting treatment, as shared at ASCO 2022
14
Mar
2022
Bionest
ASH 2021 Update: Part One
Are anti-CD38 antibodies & CAR-T treatments living up to their promise for multiple myeloma patients? We examine clinical trial results shared at ASH2021
31
Jan
2022
Bionest
What’s Next for mRNA?
Beyond COVID and cancer: In which indications will we see mRNA technology succeed next? And what technological advances might next-generation mRNA platforms offer over those used in the COVID-19 vaccines?
25
Nov
2019
Bionest
Driving CAR-T beyond oncology
Several companies and research institutions are developing potential CAR-T treatments for non-cancer indications, from heart disease to viral infection.
11
Nov
2019
Bionest
ESMO 2019: Translating Science into Better Cancer Care
The field of oncology has seen a number of significant advances in recent years. The considerable number of positive reports from the 2019 Congress of the European Society for Medical Oncology (ESMO) last month clearly reflected the meeting’s theme — the translation of scientific advances into better cancer care. AstraZeneca/Merck was one of stars...
7
Oct
2019
Bionest
New Approvals for Tumor-Agnostic Cancer Treatments — and the Questions They Raise
On August 15, the U.S. Food and Drug Administration granted accelerated approval to Genentech/Roche’s Rozlytrek (entrectinib) for the treatment of adult and adolescent patients with solid tumors that exhibit neurotrophic tyrosine receptor kinase (NTRK) fusions and for whom there are no existing effective treatments. While NTRK fusions are rare, appearing in about 1% of solid...
12
Aug
2019
Bionest
New Excitement About Antibody-Drug Conjugates in Cancer
The ability to target malignant cells without damage to surrounding healthy ones has been a long-sought goal in cancer drug development. Antibody-drug conjugates (ADCs) have been investigated as one such solution aimed at delivering more targeted therapies. ADCs — an approach first envisioned by Paul Ehrlich in the early 20th century — combine the targeting...
15
Jul
2019
Bionest
News from ASCO: Part 2
In this post, we continue our report on some of the precision medicine approaches and initiatives we noted at ASCO. Neoantigens Revitalizing Cancer Vaccine Efforts Early efforts to create cancer vaccines aimed at increasing the immune system’s exposure to tumors, but the effectiveness of first-generation vaccines created by Dendreon and others was limited....
8
Jul
2019